MYCN and neuroblastoma: Moreover, to our knowledge, we provide first evidence of VPF impacting N-MYC expression, increasing its therapeutic potential and appeal not only in targeting MYCN-A and/or N-MYC expressing NB models as well as for other N-MYC-driven malignancies.